Hormonal
MASLD is an independent risk factor for cardiovascular disease, including heart failure (particularly HFpEF), atrial fibrillation, and atherosclerosis, driven by shared mechanisms like insulin resistance and inflammation.
If you have fatty liver disease (MASLD), you are at a significantly higher risk for heart problems, including heart failure and atrial fibrillation, even if your liver enzymes are normal. This risk is driven by the same metabolic issues that cause fatty liver. You need regular cardiovascular screening and aggressive management of blood pressure, cholesterol, and blood sugar to protect your heart.
CVD has become the leading cause of mortality in MASLD... MASLD and CVD are linked through common CMRFs such as obesity, insulin resistance, T2DM, hypertension, and dyslipidemia.
Why this rating
Based on large-scale meta-analyses, observational studies, and consensus guidelines.
Source
Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease
Thang Viet Luong et al. · World Journal of Cardiology · 2025
DOI 10.4330/wjc.v17.i7.107751
More from this paper
- Lifestyle interventions, specifically achieving 7-10% body weight loss through caloric restriction and physical activity, are the cornerstone for reducing cardiovascular risk and improving hepatic steatosis in patients with metabolic-associated steatotic liver disease (MASLD).Good
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors reduce cardiovascular events and improve liver histology in MASLD patients, particularly those with type 2 diabetes or obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →